Technical Analysis for NLNK - Newlink Genetics Cor

Grade Last Price % Change Price Change
grade C 2.26 48.68% 0.7400
NLNK closed up 48.68 percent on Tuesday, January 21, 2020, on 3.18 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical NLNK trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Volume Surge Other 0.00%
New 52 Week High Strength 0.00%
Gapped Up Strength 0.00%
New 52 Week Closing Low Bearish 48.68%
Hot IPO Pullback Bullish Swing Setup 48.68%
New 52 Week Low Weakness 48.68%
Hot IPO Pullback Bullish Swing Setup 36.97%
New 52 Week High Strength 36.97%
New 52 Week Low Weakness 36.97%
Older signals for NLNK ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
RTT Cancer Drugs Chemical Compounds Organic Compounds Acute Myeloid Leukemia Ovarian Cancer Melanoma Vaccines Genentech Ebola Cancer Therapeutics Ebola Vaccine Immunotherapeutic Products Diffuse Intrinsic Pontine Glioma

Is NLNK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.395
52 Week Low 1.52
Average Volume 379,438
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.7925
Resistance 3 (R3) 2.7783 2.5867 2.7038
Resistance 2 (R2) 2.5867 2.4511 2.5938 2.6741
Resistance 1 (R1) 2.4233 2.3673 2.5050 2.4375 2.6446
Pivot Point 2.2317 2.2317 2.2725 2.2388 2.2317
Support 1 (S1) 2.0683 2.0961 2.1500 2.0825 1.8754
Support 2 (S2) 1.8767 2.0123 1.8838 1.8459
Support 3 (S3) 1.7133 1.8767 1.8163
Support 4 (S4) 1.7275